A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
Active, enrolledPhase 2Results postedLast updated 16 April 2026
What this trial tests
Phase 2 trial testing Atezolizumab in Gastric Cancer in 42 participants. Participants enrolled and being followed up; not accepting new ones.
Adults 18 to 75, any sex, with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Pathological Complete Regression (pCR) RatePrimary· Completion of neoadjuvant systemic therapy (up to approximately 16 months)
pCR is defined as no evidence of vital residual tumor cells on hematoxylin and eosin evaluation of the complete resected gastric/GEJ specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy (NAST), which will be reviewed by local pathologist..
Group
Value
95% CI
Arm A: Atezolizumab Plus Trastuzumab With XELOX (Capecitabine + Oxaliplatin)
38.1
18.1 – 61.6
Arm B: Trastuzumab With XELOX (Capecitabine + Oxaliplatin)
14.3
3.0 – 36.3
Objective Response Rate (ORR)Secondary· Randomiation to CR or PR during neoadjuvant systemic therapy (up to approximately 16 months)
Objective response rate (ORR), defined as the proportion of patients with a complete response (CR) or partial response (PR) during NAST, as determined by the investigator according to RECIST v1.1.
Group
Value
95% CI
Arm A: Atezolizumab Plus Trastuzumab With XELOX (Capecitabine + Oxaliplatin)
28.6
11.3 – 52.2
Arm B: Trastuzumab With XELOX (Capecitabine + Oxaliplatin)
33.3
14.6 – 57.0
R0 Resection RateSecondary· Surgery
R0 resection rate, defined as the proportion of patients with a microscopically margin-negative resection, in which no gross or microscopic tumor remains in the primary tumor bed and/or sampled regional lymph nodes based on evaluation by the local pathologist.
Group
Value
95% CI
Arm A: Atezolizumab Plus Trastuzumab With XELOX (Capecitabine + Oxaliplatin)
95.2
76.2 – 99.9
Arm B: Trastuzumab With XELOX (Capecitabine + Oxaliplatin)
90.5
69.6 – 98.8
Adverse events — posted to ClinicalTrials.gov
Time frame: From the first study drug to the data cutoff date: 21 March 2022 (up to approximately 12 months).
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Arm A: Atezolizumab Plus Trastuzumab With XELOX (Capecitabine + Oxaliplatin)
Serious: 0/21 (0%)
Deaths: 2/21
Arm B: Trastuzumab With XELOX (Capecitabine + Oxaliplatin)
This is a phase II, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of perioperative trastuzumab+XELOX with / without atezolizumab in participants eligible for surgery with locally advanced HER2-positive gastric cancer or adenocarcinoma of GEJ.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07388524 — Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer
· Phase 3
· not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
· Phase 2
· not yet recruiting
NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce
· Phase 2
· recruiting
NCT07461675 — Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resec
· Phase 3
· not yet recruiting
NCT07291076 — A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants Wit
· Phase 1, PHASE2
· recruiting
Other recruiting trials for Gastric Cancer
Currently open trials in the same condition.
NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer
· recruiting
NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers
· recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
· Phase 1, PHASE2
· recruiting
NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta
· Phase 3
· recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer
· active not recruiting
Other Hoffmann-La Roche trials
Trials by the same sponsor.
NCT07503340 — A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous O
· Phase 2
· not yet recruiting
NCT07298421 — A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in
· Phase 3
· recruiting
NCT07059273 — A COPD Data Registry for Participants With Frequent Exacerbations
· not yet recruiting
NCT07416526 — A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
· Phase 3
· recruiting
NCT05199688 — A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric
· Phase 3
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hoffmann-La Roche
Last refreshed: 16 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04661150.